Breaking News Instant updates and real-time market news.

EXEL

Exelixis

$13.18

0.06 (0.46%)

04:47
10/07/16
10/07
04:47
10/07/16
04:47

Exelixis announces results for cabozantinib phase 1 combination trial

Exelixis announced results from a phase 1 trial of cabozantinib in combination with nivolumab in patients with previously treated genitourinary tumors. The findings will be presented during a poster discussion session on October 9 at the European Society for Medical Oncology 2016 Congress, which is being held in Copenhagen, October 7-11. "The treatment landscape for advanced, intractable cancers such as metastatic urothelial carcinoma is continuously evolving and the use of combination therapies may improve outcomes for patients in need of new options," said Andrea Apolo, M.D., Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, the principal investigator of the trial. "Our previous correlative studies have demonstrated that cabozantinib has immunomodulatory properties that may counteract tumor-induced immunosuppression, providing the rationale for this trial.1,2 These promising early stage clinical findings support further investigation of cabozantinib in combination with nivolumab in a number of genitourinary tumors." Between July 2015 and September 2016, 24 patients were accrued with metastatic urothelial carcinoma, urachal adenocarcinoma, squamous cell carcinoma of the bladder or urethra, germ cell tumor, castration-resistant prostate cancer, renal cell carcinoma, or trophoblastic tumor and were treated in Part I of the study, which evaluated the combination of cabozantinib and nivolumab at four dose levels. The median number of prior systemic therapies was 3, and 10 patients had received 4 or more prior therapies. The objective response rate was 43 percent among the 23 patients who were evaluable for response, with one complete response and nine partial responses. Four of six patients with urothelial cancer achieved a response. The recommended doses for the ongoing expansion cohorts were determined to be cabozantinib at 40 mg daily and nivolumab at 3 mg/kg once every 2 weeks. Part II of the phase 1 trial examining the use of the triplet combination of cabozantinib, nivolumab, and ipilimumab is also ongoing.

  • 07

    Oct

  • 10

    Oct

  • 10

    Oct

EXEL Exelixis
$13.18

0.06 (0.46%)

08/04/16
STFL
08/04/16
NO CHANGE
STFL
Exelixis price target raised to $12 from $10 at Stifel
Stifel analyst Stephen Willey raised his price target on Exelixis after the company reported significantly better than expected Cabometyx and residual/off-label Cometriq sales into the newly launched indication of refractory renal cell carcinom. Willey expects the results to improve investors' confidence towards the company's growth outlook, and he says that anticipation of front-line CABOSUN results places a near-term floor on the stock. The analyst keeps a Buy rating on the shares.
08/22/16
GSCO
08/22/16
NO CHANGE
GSCO
Goldman lists companies to be in focus after Medivation deal
After Pfizer (PFE) announced it has agreed to acquire Medivation (MDVN) for $81.50 per share in cash, Goldman Sachs analyst Salveen Richter said he expects a focus on other commercial small-to-mid-cap cancer companies, including Incyte (INCY), Seattle Genetics (SGEN), ARIAD (ARIA) and Exelixis (EXEL). Also noting that Sanofi (SNY), which was pursuing Medivation, has recently suggested an interest in a rare disease transaction up to potentially as large as $20B, he would expect rare disease companies of that size - such as BioMarin (BMRN), Amicus (FOLD) and Ultragenyx (RARE) - to be in focus as well.
09/28/16
LEER
09/28/16
NO CHANGE
LEER
Exelixis selloff overdone, says Leerink
09/28/16
LEER
09/28/16
NO CHANGE
LEER
Outperform
Exelixis selloff based on ESMO abstracts overdone, says Leerink
Leerink analyst Michael Schmidt believes Exelixis' selloff following the publication of ESMO poster abstracts is overdone. The analyst notes that abstract includes updated data from a Phase Ib trial evaluating the combination of axitinib with pembrolizumab and appears to have sparked competitive concerns for Exelixis. However, he believes it is highly premature to draw conclusions at this point on the company's Cabometyx' market opportunity or potential in Renal Cell Carcinoma. Schmidt reiterates an Outperform rating on the shares. In afternoon trading, Exelixis' stock has dropped over 15% to $13.12 per share.

TODAY'S FREE FLY STORIES

GE

General Electric

$16.24

-0.535 (-3.19%)

10:35
01/19/18
01/19
10:35
01/19/18
10:35
Hot Stocks
Former GE vice chairman Wright says major issue is liabilities on balance sheet »

Speaking in a CNBC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

10:35
01/19/18
01/19
10:35
01/19/18
10:35
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

NINE

Nine Energy Services

10:31
01/19/18
01/19
10:31
01/19/18
10:31
Syndicate
Breaking Syndicate news story on Nine Energy Services »

Nine Energy Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

10:30
01/19/18
01/19
10:30
01/19/18
10:30
General news
U.S. January consumer confidence slid 1.5 points to 94.4 »

U.S. January consumer…

PAYC

Paycom

$89.86

0.74 (0.83%)

, ALRM

Alarm.com

$39.43

1.16 (3.03%)

10:29
01/19/18
01/19
10:29
01/19/18
10:29
Conference/Events
Jefferies software analyst holds an analyst/industry conference call »

Software Analyst DiFucci…

PAYC

Paycom

$89.86

0.74 (0.83%)

ALRM

Alarm.com

$39.43

1.16 (3.03%)

CA

CA Technologies

$34.19

-0.28 (-0.81%)

RHT

Red Hat

$125.41

-0.06 (-0.05%)

ORCL

Oracle

$50.43

0.2 (0.40%)

SSNC

SS&C

$49.94

0.23 (0.46%)

VMW

VMware

$136.19

0.56 (0.41%)

CTXS

Citrix

$91.38

0.19 (0.21%)

MSFT

Microsoft

$90.10

-0.04 (-0.04%)

SYMC

Symantec

$27.25

-0.27 (-0.98%)

PANW

Palo Alto Networks

$157.60

-0.22 (-0.14%)

APTI

Apptio

$24.23

0.23 (0.96%)

CHKP

Check Point

$103.20

-0.37 (-0.36%)

NICE

Nice

$93.83

1.2 (1.30%)

SPLK

Splunk

$91.43

0.86 (0.95%)

RNG

RingCentral

$53.55

0.35 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 23

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 05

    Feb

  • 06

    Feb

  • 06

    Feb

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

  • 12

    Feb

  • 26

    Feb

  • 27

    Feb

10:25
01/19/18
01/19
10:25
01/19/18
10:25
General news
The Michigan sentiment drop to a 6-month low of 94.4 »

The Michigan sentiment…

URG

UR-Energy

$0.72

-0.0279 (-3.72%)

10:25
01/19/18
01/19
10:25
01/19/18
10:25
Conference/Events
UR-Energy to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

AMZN

Amazon.com

$1,293.32

-1.68 (-0.13%)

10:25
01/19/18
01/19
10:25
01/19/18
10:25
Conference/Events
Leerink healthcare analysts hold an analyst/industry conference call »

Healthcare Analysts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 01

    Feb

  • 18

    Mar

BDX

Becton Dickinson

$233.54

1.42 (0.61%)

, ATHN

athenahealth

$125.53

-0.65 (-0.52%)

10:24
01/19/18
01/19
10:24
01/19/18
10:24
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

BDX

Becton Dickinson

$233.54

1.42 (0.61%)

ATHN

athenahealth

$125.53

-0.65 (-0.52%)

CRBP

Corbus Pharmaceuticals

$7.95

-0.25 (-3.05%)

TTD

Trade Desk

$48.36

-1.12 (-2.26%)

IPCI

Intellipharmaceutics

$0.80

-0.02 (-2.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 02

    Feb

  • 06

    Feb

Z

Zillow

$43.97

-0.57 (-1.28%)

, ZG

Zillow

$43.86

-0.49 (-1.10%)

10:24
01/19/18
01/19
10:24
01/19/18
10:24
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

Z

Zillow

$43.97

-0.57 (-1.28%)

ZG

Zillow

$43.86

-0.49 (-1.10%)

BLMN

Bloomin' Brands

$21.96

0.02 (0.09%)

PH

Parker-Hannifin

$210.94

0.4 (0.19%)

MKC

McCormick

$100.10

-2.81 (-2.73%)

WNS

WNS Holdings

$44.30

-0.98 (-2.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 26

    Feb

NKE

Nike

$66.12

2.0086 (3.13%)

, ANF

Abercrombie & Fitch

$19.45

0.5 (2.64%)

10:24
01/19/18
01/19
10:24
01/19/18
10:24
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

NKE

Nike

$66.12

2.0086 (3.13%)

ANF

Abercrombie & Fitch

$19.45

0.5 (2.64%)

CMG

Chipotle

$338.74

1.21 (0.36%)

FL

Foot Locker

$49.49

0.8999 (1.85%)

PM

Philip Morris

$107.12

2.05 (1.95%)

MO

Altria Group

$71.38

1.35 (1.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

  • 01

    Feb

  • 06

    Feb

ADT

ADT Inc.

, APO

Apollo Global

$34.07

-1.005 (-2.87%)

10:22
01/19/18
01/19
10:22
01/19/18
10:22
Syndicate
Breaking Syndicate news story on ADT Inc., Apollo Global »

ADT Inc. opens at $12.65,…

ADT

ADT Inc.

APO

Apollo Global

$34.07

-1.005 (-2.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 19

    Jan

NSPR

InspireMD

$0.17

-0.0019 (-1.11%)

10:21
01/19/18
01/19
10:21
01/19/18
10:21
Hot Stocks
InspireMD reports independent publication highlighting advantages of CGuard EPS »

InspireMD announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ODP

Office Depot

$3.51

0.01 (0.29%)

10:20
01/19/18
01/19
10:20
01/19/18
10:20
Options
Defensive option play in Office Depot »

Defensive option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:20
01/19/18
01/19
10:20
01/19/18
10:20
General news
Treasury Action: yields paused at highs after surging »

Treasury Action: yields…

10:18
01/19/18
01/19
10:18
01/19/18
10:18
Conference/Events
RBC Capital technology analysts hold an analyst/industry conference call »

Technology Analysts…

$NSD

NASDAQ Market Internals

10:17
01/19/18
01/19
10:17
01/19/18
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

10:16
01/19/18
01/19
10:16
01/19/18
10:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
01/19/18
01/19
10:15
01/19/18
10:15
General news
FX Action: The dollar »

FX Action: The dollar…

FAZ

Direxion Financial Bear 3x

$10.45

-0.1438 (-1.36%)

10:10
01/19/18
01/19
10:10
01/19/18
10:10
Options
Direxion Daily Financial Bear 3X Shares draws a notable option block »

Direxion Daily Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NINE

Nine Energy Services

10:09
01/19/18
01/19
10:09
01/19/18
10:09
Syndicate
Breaking Syndicate news story on Nine Energy Services »

Nine Energy Services IPO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

COLD

Americold Realty Trust

10:09
01/19/18
01/19
10:09
01/19/18
10:09
Syndicate
Breaking Syndicate news story on Americold Realty Trust »

Americold Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

QRVO

Qorvo

$68.76

-1.92 (-2.72%)

10:05
01/19/18
01/19
10:05
01/19/18
10:05
Technical Analysis
Technical Take: Qorvo drops, levels to watch »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:04
01/19/18
01/19
10:04
01/19/18
10:04
General news
Potential government shutdown not doing much to rattle market »

Stock futures were a bit…

ADT

ADT Inc.

, APO

Apollo Global

$34.37

-0.7 (-2.00%)

10:03
01/19/18
01/19
10:03
01/19/18
10:03
Syndicate
ADT Inc. IPO indicated to open at $12.75-$13.00 on 5M shares »

ADT Inc. priced 105M…

ADT

ADT Inc.

APO

Apollo Global

$34.37

-0.7 (-2.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 19

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.